Thioredoxin binding protein-2 mediates metabolic adaptation in response to lipopolysaccharide in vivo. by Oka, Shin-ichi et al.
Title Thioredoxin binding protein-2 mediates metabolic adaptationin response to lipopolysaccharide in vivo.
Author(s)
Oka, Shin-ichi; Liu, Wenrui; Yoshihara, Eiji; Ahsan, Md
Kaimul; Ramos, Dorys Adriana Lopez; Son, Aoi; Okuyama,
Hiroaki; Zhang, Li; Masutani, Hiroshi; Nakamura, Hajime;
Yodoi, Junji
CitationCritical care medicine (2010), 38(12): 2345-2351
Issue Date2010-12
URL http://hdl.handle.net/2433/156276





Thioredoxin binding protein-2 mediates metabolic adaptation in response 
to lipopolysaccharide in vivo.  
 
Shin-ichi Oka, PhD; Wenrui Liu, MD, PhD; Eiji Yoshihara MS; Md. Kaimul Ahsan, 
MD, PhD; Dorys Adriana Lopez Ramos, BS; Aoi Son DDS, PhD; Hiroaki Okuyama, 
MD, PhD; Li Zhang, MD; Hiroshi Masutani, MD, PhD; Hajime Nakamura, MD, 
PhD; and Junji Yodoi, MD, PhD 
 
Laboratory of Infection and Prevention, Department of Biological Response, Institute for 
Virus Research, Kyoto University, 53 Shogoin, Kawahara-cho, Sakyo-ku (SO, WL, EY, 
DALR, AS, HM, JY), Department of Experimental Therapeutics, Translational Research 
Center, Kyoto University Hospital, 54 Shogoin, Kawahara-cho, Sakyo-ku (MKA, HO, HN, 
JY), Kyoto 606-8507, Japan, Division of Systemic Life Science, Graduate School of 
Biostudies, Kyoto University, Kyoto (EY, DALR), Japan., Department of Genetic Medicine 
and Ansary Stem Cell Institute, Weill Cornell Medical College, 1300 York Avenue, New 
York, NY 10065, USA (LZ).  
 
SO and WL equally contributed to this study. 
 
The authors have not discovered any potential conflicts of interest. 
 
Supported, in part, by a New Energy and Industrial Technology Development Organization 
 2 
Fellowship Program (SO), Japan Society for the Promotion of Science (JSPS) with 
Postdoctoral Fellowships for Foreign Researchers (WL and MKA) and the Japan Society 
for the Promotion of Science (JSPS) with a Predoctoral Fellowship (EY). 
This work was supported in part by the Program for the Promotion of Fundamental Studies 
in Health Sciences of the National Institute of Biomedical Innovation (NIBIO) (JY). 
 
Correspondence: 
Junji Yodoi, MD, PhD 
Department of Biological Response, Institute for Virus Research, Kyoto University, 53 
Shogoin, Kawahara-cho, Sakyo-ku, Kytoto 606-8507, Japan. Phone: 81-75-751-4024; Fax 
81-75-761-5766; E-mail: yodoi@virus.kyoto-u.ac.jp 
 
Key words: Thioredoxin binding protein-2 (TBP-2), endotoxicemia, fatty acid oxidation 
disorder, hyperinsulinemia, hyperlipidema, hypoglycemia 
 
Present addresses: Department of Cell Biology and Molecular Medicine, Cardiovascular 
Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey 
Medical School, 185 South Orange Avenue, Newark, NJ 07101 (SO), Department of 
Developmental Biology, Weill Cornell Medical College, 1300 York Avenue, New York City, 
NY 10021 (WL), Cardiovascular Research Center, Department of Surgery, School of 
Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, 
CT 06030 (MKA), USA. Osaka Medical Center for Cancer and Cardiovascular Diseases, 
 3 
1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511 (HO), The Tazuke Kofukai Medical 
Research Institute, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480(HN), Japan.  
 4 
Abstract 
Objective: Endotoxin triggers a reorganization of the energy metabolic pathway, including 
the promotion of fatty acid utilization to adapt to a high energy demand during 
endotoxemia. However, the factors responsible for the metabolic adaptation and 
characteristic pathologies resulting from defective utilization fatty acids during endotoxin 
response have not been fully clarified. The thioredoxin binding protein-2 knockout 
(TBP-2
-/-
) mouse is an animal model of fatty acid oxidation disorder. The aim of this study 
was to determine whether and how TBP-2 is involved in metabolic regulation in a 
lipopolysaccharide (LPS)-induced endotoxemia model in mice. 
Design: Prospective animal trial. 
Setting: Research laboratory. 
Subjects: TBP-2
-/-
 and wild control mice.  
Intervention: TBP-2
-/-
 and wild control mice were intraperitoneally injected with LPS. 
Mortality, serum levels of markers of hepatorenal injuries, cytokines, insulin, glucose and 
lipid derivatives, and the hepatic signaling pathway regulating gluconeogenesis were 
investigated.  
Measurements and main results: Following the administration of LPS, TBP-2
-/-
 mice 
showed a predisposition for death without any significant elevation of inflammatory 
cytokines, compared to the wild mice. LPS-challenged TBP-2
-/-
 mice showed fat deposition 
in the liver and kidney, organ injuries, glycogen depletion, and elevation of serum lipid 
derivatives such as free fatty acids, triglyceride and cholesterol. Hyperinsulinemia and 
hypoglycemia were observed in TBP-2
-/-
 mice after LPS injection. Death due to the LPS 
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administration was prevented by supplementation of glucose. Phosphorylation of Akt and 
FoxO1, an inhibitory pathway of gluconeogenesis in the liver of LPS-challenged TBP-2
-/-
 
mice was demonstrated, suggesting the enhancement of insulin signaling. 
Conclusions: TBP-2 is involved in metabolic control during LPS-induced endotoxemia. 
After the LPS challenge, TBP-2
-/-
 mice showed several characteristic aspects, such as 
hepatorenal injuries, and dysregulation of the lipid and glucose metabolisms. Furthermore, 
hypoglycemia promoted by hyperinsulinemia may be a critical risk factor for mortality in 
circumstances where fatty acid utilization is impaired during endotoxemia. 
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Introduction 
Sepsis and septic shock that are characterized as widespread and systemic inflammatory 
reactions that can be triggered by an increase in the circulating levels of endotoxins, which 
are provoked by bacterial infection, representing a major cause of mortality in hospitalized 
patients[1, 2]. Mitochondria fatty acid oxidation is considered to be important for energy 
homeostasis, especially under conditions requiring a high energy demand, such as fasting 
and infection[3]. Several reports have shown that endotoxins alter energy metabolism, 
including the augmentation of glucose and fatty acid utilization, most probably due to the 
high energy demand in endotoxemia and/or septic conditions[4-7]. However, excessive 
endotoxins impair the function of the mitochondria, which in turn results in impaired fatty 
acid utilization[8-10]. Several symptoms, such as multiple organ failure, hypoglycemia, 
hyperlipidemia, and liver steatosis are commonly observed in sepsis, endotoxemia and fatty 
acid oxidation disorders (FAODs), also known as the Reye-like syndrome, which is caused 
by both inheritable and heritable defects of mitochondria fatty acid oxidation[11-15]. In 
spite of those similar pathologies, as well as the existence of individuals with insufficient 
fatty acid oxidation, the molecular mechanism and consequence of insufficient fatty acid 
oxidation in endotoxemia remains to be elucidated.  
TRX-binding protein-2 (TBP-2) was identified as a binding protein of Thioredoxin-1 
(TRX) by yeast two-hybrid screening using TRX as bait[16]. TBP-2 binds to TRX through 
the formation of a mixed disulfide[17], which results in competitive inhibition of the other 
target molecules of TRX[16, 18]. Growing evidence has suggested that TBP-2 serves a 
wide range of biological functions, including tumor suppression, cellular development and 
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metabolic control[19-21]. TBP-2 knockout (TBP-2
-/-
) mice have defective fatty acid 
utilization, thereby showing compatible phenotypes of human FAODs under fasting 
conditions[20, 22, 23]. We hypothesized that TBP-2 is involved in fatty acid oxidation in 
endotoxemia, and therefore, that TBP-2
-/- 
mice provide a suitable animal model to evaluate 
the sequential pathology resulting from the inability to utilize fatty acids during 
endotoxemia.  
In the present study, we explored the role of TBP-2 in an animal model of endotoxemia 
using intraperitoneal injections of lipopolysaccharide (LPS), a cell wall component derived 
from gram-negative bacteria, to TBP-2
-/- 
mice. Our results demonstrated that TBP-2
-/- 
mice 
showed a high mortality with pathologies partly similar to those shown in human septic 
patients, as well as FAODs, after LPS administration, suggesting that the inability to utilize 
fatty acid is a crucial risk factor for mortality in endotoxemia. 
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Materials and methods 
Animals 
Thioredoxin binding protein-2-deficient (TBP-2
-/-
) mice were backcrossed for at least 5 
generations to C57BL/6 backgrounds. All of the mice were housed in the specific 
pathogen-free animal facility at the Institute for Virus Research, Kyoto University. All of 
the procedures involving animals were performed in accordance with the protocols 
approved by the Kyoto University Institutional Animal Care and Use Committee. 
 
Western blot analysis 
The liver was dissected and lysed with lysis buffer containing 1% NP40, 1% 
Na-deoxydulate, 0.1% SDS, 20 mM Tris (pH7.5), 5 mM EDTA, 150 mM NaCl, protease 
inhibitors (Complete, Roche) and phosphatase inhibitors (PhosStop, Roche). Western blot 
analysis was performed using an ECL Western blotting detection system (Amersham 
Biosciences), according to the manufacturer’s instructions. Anti-Akt, anti-phosphorylated 
specific Akt (Ser473), anti-FoxO1 and anti-phosphorylated specific FoxO1 (Ser256) were 
purchased from Cell Signaling. 
 
Induction of endotoxemia  
LPS from Escherichia coli (055:B5, Sigma, St. Louis, MO) was intraperitoneally 
injected (i.p.) with 1, 5 or 25 mg/kg of body weight in 200 l of saline. Unless indicated 
otherwise, one mg/kg of body weight LPS was injected. Animals of sham control groups 
were administered i.p. with 200 L of saline only. Mortality was recorded every 8 hours 
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and continued up to 120 hours after LPS injection.  
 
Histopathology 
Under anesthesia, the liver and kidney were removed at appropriate time points, fixed 
in 10% buffered formalin, and embedded in paraffin, followed by staining with 
hematoxylin and eosin (H & E), periodic acid-schiff(PAS) and anti-NIMP-R14 antibody 
(Abcam). 
 
Blood Biochemical Examine 
Mice were injected with LPS in saline or saline alone, as mentioned above. Blood was 




Mice were injected with LPS in saline or saline alone, as mentioned above. Blood was 
collected from the retro-orbital at the indicated times, and clarified sera samples were 
stored at -80C. Serum interferon- (IFN-, INF-, tumor necrosis factor- (TNF-), 
interleukin-6 (IL-6), and IL-10, monocyte chemoattractant protein-1 (MCP-1), macrophage 
inflammatory protein-2 (MIP-2) levels were determined using ELISA Development 
Systems (R & D Systems, Inc., Minneapolis, MN). 
 
Semiquantitative and quantitative RT-PCR analysis 
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Following LPS injection, the liver was removed, and the total RNA was extracted using 
TRIzol reagent (Life Technologies, Inc), according to the manufacturer’s instructions. 
Reverse
 
transcription was performed with a SuperScript III First-Strand
 
Synthesis System 
kit (Invitrogen). Real-time RT-PCR was performed using SYBR Premix Ex Tag 





 -actin sense 
(5'-ATGGATGACGATATCGCTGCGCT-3', and antisense 
(5'-TAGAAGCACTTGCGGTGCACGAT-3').
 
Amplification of the products was not 
saturated with the number of cycles we performed.  
 
Statistics Analysis 
Results were expressed as mean  SD. Statistical comparisons were performed by 
1-way ANOVA, followed by Student-Newman-Keul’s post-hoc analysis. Survival data were 
evaluated using the kaplan-meier log-rank test. Findings of P<0.05 were considered as 






 mice are susceptible to LPS-induced endotoxemia.  
In order to investigate the role of TBP-2 in response to LPS, wild, TBP-2 heterozygous 
knockout (TBP-2
+/-
) and homozygous knockout (TBP-2
-/-
) mice were injected 
intraperitoneally (i.p.) with doses of 1, 5, or 25 mg/kg of body weight of LPS. As shown in 
Fig. 1A, both male and female TBP-2
-/-
 mice showed a significant susceptibility to LPS, 
compared with the wild mice in all of the doses we tested. Before death, these mice showed 
severe debility and hypothermia (data not shown). This susceptibility was also observed in 
ICR and Balb/c genetic background TBP-2
-/-
 mice, suggesting that the high susceptibility to 
LPS does not depend on the genetic background of mice (Supplementary Fig. 1A). TBP-2
+/-
 
mice showed a tendency for a high mortality, compared to wild mice after LPS 
administration. RT-PCR examination revealed that TBP-2 expression was up-regulated in 
the liver after 1 hour after the LPS administration and the expression was sustained for 24 
hours (Fig. 1B). LPS-induced TBP-2 expression was attenuated in TBP-2
+/-
 mice, compared 
to wild mice, suggesting that up-regulated TBP-2 may partly contribute to animal survival 
in the response to LPS (Fig. 1C). These results suggested that TBP-2 is an endotoxin 
response gene and plays an important role in animal survival in LPS-induced endotoxemia.  
 
Hypercytokinemia is not observed in LPS-challenged TBP-2
-/-
 mice. 
Since hypercytokinemia has been associated with high mortality in several animal 
models showing a high susceptibility to LPS, we then investigated whether or not there 
were any differences between wild and TBP-2
-/-
 mice in the LPS-induced production of 
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inflammatory cytokines. The serum levels of TNF, IL-6, IL-10, INF INF, MCP1 and 
MIP2 were measured after LPS injection. As shown in Fig. 2A, TBP-2
-/-
 mice did not show 
higher levels of those cytokines compared to wild mice, but rather slightly lower levels of 
INF- and MCP-1 at particular time points. As consistent with cytokine and chemokine 
levels, neutrophil infiltrations were not significantly changed between the wild and TBP-2
-/-
 
mice (Figure 2B). These results suggested that the high susceptibility of TBP-2-/- mice was 
not associated with the enhancement of cytokine production.  
 
Fat accumulation in TBP-2
-/-
 mice following LPS injection 
Histological studies were performed in order to investigate the abnormality of TBP-2
-/-
 
mice. Hematoxylin and eosin staining revealed that microvesicular and macrovesicular 
steatosis occurred in the liver and kidney of TBP-2
-/-
 mice, but not in the wild mice after 
LPS administration. Mild hepatic steatosis was also observed in TBP-2
+/-
 mice after LPS 
administration (Supplementary Fig. 2). In addition, the glomerular structure was destroyed 
in the kidney of LPS-injected TBP-2
-/-
 mice (Fig. 3A). 
Several serum makers were examined in order to investigate those organ injuries. As 
shown in Fig. 3B, the levels of alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), lacate dehydrogenase (LDH), blood urea nitrogen (BUN) and creatinene were 
elevated in TBP-2
-/-
 mice by LPS-injection, compared to wild mice, indicating liver and 
renal injuries. Endotoxin-induced organs ischemia occasionally accompanies organ injuries, 
but we could not find any ischemic necrosis in the livers and kidneys or reduced liver 
weight, an index of reduced liver blood flow in TBP-2
-/-
 mice (Supplementary Fig. 3). 
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These results suggested that LPS causes fat accumulation as well as those organ injuries in 
TBP-2
-/-
 mice.  
 
Plasma lipid derivatives are accumulated in TBP-2
-/-
 mice following LPS injection 
Since steatosis was found in the liver and kidney of TBP-2
-/-
 mice, we conducted 
examinations to determine if the lipid metabolism was dysregulated in those mice. As 
shown in Fig. 4, the plasma levels of free fatty acids, triglyceride, total cholesterol and 
phospholipids were increased in TBP-2
-/-
 mice, but not in wild mice, after LPS injection. 
LPS-induced hyperlipidemic features were also observed in C57B/6 F12 genetic 
background of TBP-2
-/-
 mice (Supplementary Fig. 1B). We have previously shown that 
these hyperlipidemic features were observed in TBP-2
-/-
 mice during a fasting state[20]. 
Interestingly, the increased levels of the lipid derivatives were significant in the LPS 
injection mice, rather than with fasting. In addition, TBP-2
-/-
 mice showed a resistance 
against LPS-induced anorexia (Fig. 4B), indicating that the dyslipidemia is not simply due 
to LPS-induced anorexia in TBP-2
-/- 
mice. Thus, TBP-2 has an essential role in lipid 
homeostasis during LPS response. Notably, TBP-2
-/-
 mice show an insufficient fatty acid 
utilization[20], and therefore, accumulated free fatty acids were observed in those mice 
without LPS injection or fasting. 
 
Dysregulation of glucose metabolism triggers the fatality of LPS-injected TBP-2
-/-
 mice. 
Hypoglycemia is occasionally observed in endotoxemia. To investigate whether 
TBP-2
-/-
 mice have abnormalities in the glucose metabolism during LPS response, the 
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serum levels of glucose and insulin were examined. Plasma glucose levels were reduced at 
24 hours after LPS injection in wild mice, while TBP-2
-/-
 mice showed more severe 
hypoglycemia (Fig. 5A). Plasma levels of insulin were significantly up-regulated in the 
TBP-2
-/-
 mice (Fig. 5B). PAS staining revealed that glycogen was depleted in the liver of 
TBP-2
-/-
 mice after LPS injection, compared to wild mice (Fig. 5C), suggesting that 
accelerated glucose consumption due to hyperinsulinemia with insufficient fatty acid 
utilization is the more dominant constraint, compared to insulin-mediated inhibition of 
glycogen catabolism. 
To investigate the role of hypoglycemia in the observable mortality, we examined 
whether glucose supplementation reduces the lethality induced by LPS in TBP-2
-/-
 mice. As 
shown in Fig 5D, lethality was not reduced in LPS-challenged TBP-2
-/-
 mice when these 
mice were housed with 20% glucose available in drinking water. In contrast, lethality was 
reduced in these mice by an intraperitoneal injection of glucose. Thus, forced glucose 
supplementation reduces the LPS-induced lethality in TBP-2
-/-
 mice. Taken together, this 




Insulin signaling is activated after LPS-challenge in TBP-2
-/-
 mice. 
Insulin promotes hypoglycemia through the induction of glucose uptake and the 
inhibition of gluconeogensis, which are mediated by Akt kinase. To investigate whether 
LPS-induced hyperinsulinemia activates Akt kinase, the phosphorylation levels of Akt were 
examined. As shown in Fig. 6A, LPS challenge significantly induced Akt phoshorylation in 
TBP-2
-/-
 mice, compared to the wild mice. Akt phosphorylates and inhibits FoxO1, a crucial 
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transcription factor promoting gluconeogenesis[24]. As is consistent with the activation of 
Akt, phosphorylation levels of FoxO1 were up-regulated in TBP-2
-/-
 mice after LPS 
injection (Fig. 6B). These results suggested that LPS-induced hyperinsulinemia activates 
insulin signaling to enhance hypoglycemia in TBP-2
-/-
 mice during LPS response.  
 
Discussion 
In our present study, we reported that TBP-2
-/-
 mice showed a high susceptibility to 
LPS-induced lethality. Since the TBP-2
-/-
 mouse is an animal FAODs model[20], our data 
strongly suggested that insufficient fatty acid utilization is a risk factor for mortality during 
endotoxemia. TBP-2
-/-
 mice showed pathological features after LPS administration, such as 
fat infiltration into the liver and kidneys, multiple organ injuries, elevations of plasma lipid 
derivatives, hyperinsulinemia and hypoglycemia, which are most certainly enhanced by the 
inability for fatty acid utilization, resulting from the loss of TBP-2. Indeed, several 
characteristic features have also been reported in human patients developing sepsis as well 
as FAODs[12, 25, 26]. Recently, it was reported that dysregulations of mitochondria protein 
synthesis and gene expression were often observed in septic patients treated in an intensive 
care unit[27]. Taken together, those mitochondria dysfunctions might be not only the 
resultant pathology, but also a deterioration factor in endotoxemia. 
The LPS-induced pathology of TBP-2
-/-
 mice were quite similar to fasting mice, such as 
multiple organ injuries, liver and renal steatosis (Fig. 3A and Supplementary Fig. 4), high 
levels of plasma lipid derivatives (Fig. 4A), hyperinsulinemia and hypoglycemia [20, 28]. 
Glucose supplementation also rescues fasting-induced abnormalities in TBP-2
-/-
 mice such 
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as mortality and increased plasma revels of AST, ALT and creatinine[20]. Even though the 
triggering factor is different between fasting and LPS administration, most of the 
abnormalities seen seem to be similar. As is the case with TBP-2
-/-
 mice, it has been 
reported that hyperinsulinemia associates with hypoglycemia in patients with Reye-like 
syndrome harboring mutation in medium- and short-chain l-3-hydroxy-acyl-CoA 
dehydrogenase (M/SCHAD)[29]. It is likely that inability of fatty acid utilization augments 
glucose consumption to adapt high energy demand, which is enhanced by insulin. Although 
insulin is supposed to inhibit glycogen catabolism, glycogen was significantly depleted but 
that is not enough to normalize hypoglycemia in TBP-2
-/-
 mice. These results suggested that 
glucose is predominantly utilized during endotoxemia in circumstance where fatty acid is 
not available as an energy source due to impaired fatty acid catabolism. Even though it is 
currently unknown if hyperinsulinemia is associated with hypoglycemima or exacerbates 
abnormalities in endotoxemia, our data strongly suggested that hyperinsulinemia resulting 
in hypoglycemia is a critical risk factor in patients having insufficient fatty acid utilization.  
In conclusion, this study suggests that mitochondria function inability is a risk factor 
for mortality in endotoxemia, and that the resultant pathological features are multi-organ 
injury, hypoglycemia and dyslipidemia without significant changes in cytokine levels. 
Since mitochondria function is disturbed by inborn defects as well as by an infection itself, 
these findings may be a good clue to develop novel therapeutic treatment for improving 
mortality in human patients. Although it remains unclear whether TBP-2 has a role in 
endotoxin-induced fatal syndrome following an infection in humans, our present study 
provides some intriguing implications and the possibility that TBP-2 is involved in such 
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biological responses. Hence, TBP-2 may be a novel target molecule for therapeutic 
approaches for use in human diseases.  
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Figure 1. (A) Survival rates of TBP-2
-/-





and wild mice were injected with the indicated dose of LPS. The number of mice examined 
was 8-12 (Male, 1 mg/kg), 8-11 (Female, 1 mg/kg), 8-9 (Male, 5 mg/kg), 8 (Female, 5 
mg/kg), 10-11 (Male, 25 mg/kg) and 8 (Female, 25 mg/kg) in each experimental group. 
(B-C) TBP-2 expression in the liver of wild and TBP-2
-/-
 mice following LPS 
administration. Indicated time points (B) and 24 hours (C) after LPS injection. TBP-2 
expression levels in the liver were analyzed with RT-PCR. 
 
Figure 2. (A) Cytokine expressions in TBP-2
-/-
 mice following LPS administration. TBP-2
-/-
 
and wild mice were sacrificed at appropriate time points after LPS injection, respectively. 
Serum levels of indicated cytokines were analyzed. The number of mice examined was 3-8 
(TNF-), 3-7 (IL-10), 3-7 (IL-6), 3-8 (IFN-), 3-5 (IFN-), 4-5 (MCP-1) and 3-5 (MIP-2) 
in each experimental group. (B) Neutrophil infiltration in TBP-2
-/-
 mice following LPS 
administration. Anti-NIMP-R14 immunostaining were performed to examine neutrophil 
infiltration into the liver. The NIMP-R14 positive cells were stained as brown. 
 
Figure 3. (A) Representative histopathology of the liver and the kidneys of TBP-2
-/-
 mice 
following LPS administration. H & E staining was performed with dissected livers and 
kidneys at indicated time points after LPS administration. (B) Serum biochemical 
examination for the hepatocyte and renal cells injuries in TBP-2
-/-
 mice following LPS 
administration. Serum levels of AST, ALT, LDH, BUN and creatinine were examined at the 
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indicated time points after LPS administration. The number of mice examined was 3-9 
(AST), 4-9 (ALT), 3-9 (LDH), 3-9 (BUN) and 4-9 (Creatinine) in each experimental group. 
 
Figure 4. (A) Serum biochemical examination for lipid metabolism in TBP-2
-/-
 mice 
following LPS administration or fasting. Serum levels of free fatty acid, triglyceride, total 
cholesterol, and phospholipid were examined at the indicated time points after LPS 
administration or fasting. The number of mice examined was 3-10 (Free fatty acids), 3-14 
(Triglyceride), 3-10 (Total cholesterol) and 3-10 (phospholipid) in each experimental group. 
(B) Amount of Food intake of TBP-2
-/-
 mice following LPS administration. TBP-2
-/-
 and 
wild mice were injected with LPS. The amount of food intake per 24 hours was examined 
at the indicated time points. At least 3 mice that survived at the indicated time points were 
examined for each experimental group. 
 
Figure 5. The glucose metabolism of TBP-2
-/-
 mice following LPS administration. Serum 
levels of glucose (A) and insulin (B) were examined at the indicated time points following 
LPS administration. The number of mice examined was 3-5 (A) and 4-13 (B) in each 
experimental group. (C) TBP-2
-/-
 mice were treated with free drinking of 20% glucose(solid 
line), or injected with 4g/kg of body weight of glucose in distilled water (broken line) 24 
hours following LPS administration. The survival rate of the animals was observed during 
the following 96 hours. The number of mice examined was 3 (free drinking), 9 (injection) 
in each experimental group.  
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Figure 6. LPS activates insulin signaling in TBP-2
-/-
 mice. Phosphorylation levels of Akt 
(A) and FoxO (B) were examined by western blot analyses 24 hours after LPS 
administration. Coomassie brilliant blue (CBB) staining indicated that an equal amount of 
proteins were applied. The signal intensities were measured by the ImageJ program. 
Phosphorylated protein signals were individually divided by total protein signals. The 
signal intensities of the phosphorylated forms are shown relative to the control value (wild 
mice with saline treatment), which was taken as 1. The results are shown as the mean  S.D. 
of 3 to 6 samples. (lower panels).  
 
Supplementary Figure 1. (A) Survival rates of TBP-2
-/-
 of ICR and Balb/c genetic 
background mice following lipopolysaccharides (LPS) injection. The survival rates of these 
mice were observed for 96 hours following LPS administration. At least 4 mice were 
examined for each experimental group. (B) LPS induces organ injuries and metabolic 
dysregulation in C57B/6 F12 background TBP-2
-/-
 mice. Indicated serum makers and 
metabolites were examined in TBP-2
-/-
 of C57B/6 F12 background mice 24 hours after LPS 
administration. The number of mice examined was 3-5 (wild mice) and 3 (TBP-2
-/-
 mice) in 
each experimental group.  
 
Supplementary Figure 2. LPS induces mild hepatic steatosis in TBP-2
+/-
 mice. H & E 
staining was performed in the liver 24 hours after LPS administration. Sections from 
individual mice were shown. 
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Supplementary Figure 3. Liver weight was not changed in TBP-2
-/-
 mice. Liver 
weight/body weight ratio was evaluated 24 hours after LPS administration.  
 
Supplementary Figure 4. Representative histopathology of the liver and the kidneys of 
TBP-2
-/-
 mice following fasting and LPS administration. H & E staining was performed 
using liver and kidneys at 24 hours after food deprivation or LPS injection. In addition to 
microvesicular and macrovesicular steatosis features after fasting and LPS administration, 
neutral lipid accumulation was assessed by Oil Red O staining in free feeding and fasting 
states of TBP-2
-/-
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